Clinical Trial Update: Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating irinotecan and cytarabine in patients with refractory or recurrent acute myeloid leukemia or chronic myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Cytarabine (Cytosar-U) (cytarabine)
• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Leukemia | Phase 1 | Status: COMPLETED